| 摘要: |
| 目的:研究错配修复基因2(hMSH2)在膀胱尿路上皮癌中的表达及其与临床预后的关系。方法:应用SP 免疫组化法检测72 例膀胱尿路上皮癌和49 例膀胱正常黏膜组织中hMSH2 的表达状况，分析不同膀胱尿路上皮癌患者临床病理特征的hMSH2 蛋白阳性表达率，Kaplan-Meier 生存分析膀胱尿路上皮癌hMSH2 蛋白阳性表达与5 年复发的关系。结果:在膀胱尿路上皮癌中hMSH2 蛋白表达的阳性率为34.72%(25/72)，低于正常膀胱黏膜的91.84%(45/49)，差异有统计学意义(P <0.01) ；hMSH2 蛋白表达阳性率在Ⅰ级膀胱尿路上皮癌中为44.4%(20/45)，高于Ⅱ～Ⅲ级的18.51%(5/27)，差异有统计学意义(P <0.05)。在膀胱尿路上皮癌临床分期Tis~T1 期中hMSH2 蛋白表达阳性表达率为43.48%(20/46)，高于T2~T4 期的19.23%(5/26)，差异有统计学意义(P <0.05)。Kaplan-Meier 生存分析显示hMSH2 表达阳性者的5 年复发率为19.35%(6/31)，低于hMSH2 表达阴性者的46.34%(19/41)，差异有统计学意义(P <0.05)。结论:hMSH2 蛋白在膀胱尿路上皮癌中表达较正常组织低，与其分化程度、临床分期及5 年复发率有关，hMSH2 可能参与了膀胱尿路上皮癌的演化和进展。 |
| 关键词: 膀胱肿瘤 错配修复基因-2 免疫组织化学 |
| DOI：10.3969/j.issn.1007-6948.2020.03.022 |
| 投稿时间：2019-07-13 |
| 基金项目:浙江省金华市科技局重点计划资助项目(2017-3-016) ；浙江省医药卫生科技计划项目(2019-KY766) |
|
| Expression and its Clinical Prognosis of hMSH2 in Bladder Urothelial Carcinoma |
| ZHANG Chun-ting,LU Rong,XU Yong |
| Department of Urology, Jinhua City People’s Hospital, Jinhua (321000), China |
| Abstract: |
| Objective To investigate the expression of hMSH2 in bladder urothelial carcinoma and its clinical prognosis. Methods SP immunohistochemistry was used to detect expression of hMSH2 in 72 cases of bladder urothelial carcinoma and 49 cases of bladder normal tissues. The results and the clinical data of bladder urothelial carcinoma were analyzed. Kaplan-Meier survival was used to analyze the relationship between hMSH2 and 5-year recurrence of bladder urothelial carcinoma. Results The positive rate of hMSH2 protein expression of bladder urothelial carcinoma and normal bladder tissue was respectively 34.72%(25/72) and 91.84%(45/49),hMSH2 protein expression positive rate were 44.4% (20/45) at level Ⅰ , 18.51% at level Ⅱ - Ⅲ (5/27), the difference is significant between groups (P < 0.05). The positive expression rates of hMSH2 protein in Tis ~ T1 and T2 ~ T4 were respectively 43.48%(20/46) and 19.23%(5/26), the difference was significant (P <0.05).Kaplan-Meier survival analysis showed that the recurrence rate of hMSH2 expression and negative hMSH2 expression were respectively 19.35%(6/31) and 46.34%(19/41) in the 5-year follow-up, the difference was significant (P <0.05). Conclusion The decreased expression of hMSH2 protein in bladder urothelial carcinoma is related to its differentiation, clinical stage and 5-year recurrence. hMSH2 may be involved in the evolution and progression of bladder urothelial carcinoma. |
| Key words: Bladder tumor hMSH2 genes immunohistochemistry |
